Next Article in Journal / Special Issue
IgE Antibodies: From Structure to Function and Clinical Translation
Previous Article in Journal
Preferential Identification of Agonistic OX40 Antibodies by Using Cell Lysate to Pan Natively Paired, Humanized Mouse-Derived Yeast Surface Display Libraries
Open AccessReview

Macro- and Micro-Heterogeneity of Natural and Recombinant IgG Antibodies

by Alain Beck 1,* and Hongcheng Liu 2,*
1
Biologics CMC and developability, IRPF, Center d’immunologie Pierre Fabre, St Julien-en-Genevois CEDEX, 74160 Saint-Julien en Genevois, France
2
Anokion, 50 Hampshire Street, Suite 402, Cambridge, MA 02139, USA
*
Authors to whom correspondence should be addressed.
Antibodies 2019, 8(1), 18; https://doi.org/10.3390/antib8010018
Received: 22 December 2018 / Revised: 19 January 2019 / Accepted: 13 February 2019 / Published: 19 February 2019
(This article belongs to the Special Issue Structure and Function of Antibodies)
Recombinant monoclonal antibodies (mAbs) intended for therapeutic usage are required to be thoroughly characterized, which has promoted an extensive effort towards the understanding of the structures and heterogeneity of this major class of molecules. Batch consistency and comparability are highly relevant to the successful pharmaceutical development of mAbs and related products. Small structural modifications that contribute to molecule variants (or proteoforms) differing in size, charge or hydrophobicity have been identified. These modifications may impact (or not) the stability, pharmacokinetics, and efficacy of mAbs. The presence of the same type of modifications as found in endogenous immunoglobulin G (IgG) can substantially lower the safety risks of mAbs. The knowledge of modifications is also critical to the ranking of critical quality attributes (CQAs) of the drug and define the Quality Target Product Profile (QTPP). This review provides a summary of the current understanding of post-translational and physico-chemical modifications identified in recombinant mAbs and endogenous IgGs at physiological conditions. View Full-Text
Keywords: critical quality attributes; comparability; developability; glycosylation; quality target product profile; mass spectrometry; post-translational modifications; proteoforms; safety critical quality attributes; comparability; developability; glycosylation; quality target product profile; mass spectrometry; post-translational modifications; proteoforms; safety
MDPI and ACS Style

Beck, A.; Liu, H. Macro- and Micro-Heterogeneity of Natural and Recombinant IgG Antibodies. Antibodies 2019, 8, 18.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop